116
Participants
Start Date
March 13, 2018
Primary Completion Date
April 13, 2023
Study Completion Date
April 13, 2023
evinacumab
Intravenous (IV) administration
Clinical Trial Site, Roma
Regeneron Study Site, Vienna
Regeneron Study Site, Johannesburg
Clinical Trial Site, Camperdown
Rgeneron Study Site, Kyiv
Clinical Trial Site, Perth
Regeneron Study Site, Innsbruck
Regeneron Study Site, Cape Town
Clinical Trial Site, New York
Clinical Trial Site, Marseille
Regeneron Study Site, Kallithea
Clinical Trial Site, Philadelphia
Clinical Trial Site, Dijon
Clinical Trial Site, Boca Raton
Clinical Trial Site, Cincinnati
Clinical Trial Site, Ioannina
Clinical Trial Site #1, Kharkiv
Clinical Trial Site #2, Kharkiv
Clinical Trial Site, Dallas
Clinical Trial Site, Dallas
Clinical Trial Site, Paris
Clinical Trial Site, Ivano-Frankivsk
Clinical Trial Site, Napoli
Clinical Trial Site, Los Angeles
Clinical Trial Site, Portland
Clinical Trial Site, Boston
Clinical Trial Site, Chicoutimi
Clinical Trial Site, Québec
Regeneron Study Site, Prague
Clinical Trial Site, Ōbu
Regeneron Study Site, Kurume
Regeneron Study Site, Nishinomiya
Regeneron Study Site, Kanazawa
Regeneron Study Site, Kita-ku
Regeneron Study Site, Suita
Regeneron Study Site, Suita
Clinical Trial Site, Amsterdam
Clinical Trial Site, Kyiv
Regeneron Pharmaceuticals
INDUSTRY